A phase III study to evaluate the efficacy and safety of front-line therapy with alemtuzumab (Campath, MabCampath) vs chlorambucil in patients with progressive B-cell chronic lymphocytic leukemia

Trial Profile

A phase III study to evaluate the efficacy and safety of front-line therapy with alemtuzumab (Campath, MabCampath) vs chlorambucil in patients with progressive B-cell chronic lymphocytic leukemia

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2016

At a glance

  • Drugs Alemtuzumab (Primary) ; Chlorambucil (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Sanofi Oncology
  • Most Recent Events

    • 05 Nov 2007 Results published in Journal of Clinical Oncology.
    • 30 Oct 2006 Status change
    • 10 Oct 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top